YAQII
Lv7
4410 积分
2021-03-16 加入
-
Re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate
4个月前
已采纳
-
Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489-91
4个月前
已采纳
-
Re: Cristina Masini, Cinzia Iotti, Ugo De Giorgi, et al. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. Eur Urol. 2022;81:274-82
4个月前
已采纳
-
Reply to Jas Singh's Letter to the Editor re: Marc Sbizzera, Nicolas Morel-Journel, Alain Ruffion, et al. Rectourethral Fistula Induced by Localised Prostate Cancer Treatment: Surgical and Functional Outcomes of Transperineal Repair with Gracilis Muscle Flap Interposition. Eur Urol. 2022;81:305-12
4个月前
已采纳
-
Re: Changes in Prostate-specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening
4个月前
已采纳
-
Optimal Dissemination of Scientific Manuscripts via Social Media: A Prospective Trial Comparing Visual Abstracts Versus Key Figures in Consecutive Original Manuscripts Published in European Urology
4个月前
已采纳
-
Reply to Francesco Montorsi, Simone Scuderi, Alberto Briganti, and Giorgio Gandaglia's Letter to the Editor re: Melline G.M. Schilham, Mark Rijpkema, Tom Scheenen, et al. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come. Eur Urol 2022;82:578-80
4个月前
已采纳
-
Re: George J. Netto, Mahul B. Amin, Eva M. Compérat, et al. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.015
4个月前
已采纳
-
Re: Percentage Gleason Pattern 4 and PI-RADS Score Predict Upgrading in Biopsy Grade Group 2 Prostate Cancer Patients Without Cribriform Pattern
4个月前
已采纳
-
A Transgender Patient with Prostate Cancer: Lessons Learnt
4个月前
已采纳